US OptionsDetailed Quotes
EQ240719C7500
- 0.05
- 0.000.00%
15min DelayTrading May 24 12:55 ET
0.00High0.00Low
0.00Open0.05Pre Close0 Volume77 Open Interest7.50Strike Price0.00Turnover845.38%IV908.01%PremiumJul 19, 2024Expiry Date0.00Intrinsic Value100Multiplier9DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.1544Delta0.2336Gamma14.98Leverage Ratio-0.0123Theta0.0000Rho2.31Eff Leverage0.0003Vega
Equillium Stock Discussion
$Equillium(EQ.US)$
Equillium Inc. (Nasdaq: EQ), a clinical-stage biotechnology company, recently announced promising topline results from its Phase 2 proof-of-concept (PoC) study of EQ101 in adult patients suffering from moderate, severe, or very-severe alopecia areata (AA). This autoimmune condition, driven by an immune cell attack on hair follicles, leads...
Equillium Announces Positive Topline Data From Phase 2 Study of EQ101 in Alopecia Areata
Equillium Inc: EQ101 Was Well Tolerated in Subjects With Alopecia Areata With No Serious Adverse Events Reported
$Iovance Biotherapeutics(IOVA.US)$ Phase 2
$Supernus Pharmaceuticals(SUPN.US)$ Phase 2a
$BRANDES INTERNATIONAL ETF(BINV.US)$ Phase 2a
$MorphoSys(MOR.US)$ Phase 2
$Nuvation Bio(NUVB.US)$ Phase 2
$ALX Oncology(ALXO.US)$ Phase 2
$BioXcel Therapeutics(BTAI.US)$ Phase 2
$Purple Biotech(PPBT.US)$ Phase 2
$Arcus Biosciences(RCUS.US)$ Phase 2
$Medicenna Therapeutics(MDNAF.US)$ Phase 2b
$Affimed NV(AFMD.US)$ Phase 2
$Barinthus Biotherapeutics(BRNS.US)$ Phase 2b...
NEWS
Equillium Announces Interim Enrollment Achieved in Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease
Equillium (Nasdaq: EQ) has surpassed the interim enrollment target in its Phase 3 EQUATOR study of itolizumab for acute graft-versus-host disease (aGVHD). Over 100 patients from more than 100 clinical trial sites in 12 countries are participating. Interim data will be reviewed by an independent data monitoring committee in Q3, which will trigger a thre...
No comment yet